These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 3163042)
21. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease. Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691 [No Abstract] [Full Text] [Related]
22. [Adynamic bone disease in kidney failure. Role of aluminum]. Cohen-Solal ME; Sebert JL; Morinière P; Fournier A Rev Rhum Ed Fr; 1993 May; 60(5):361-4. PubMed ID: 8167643 [No Abstract] [Full Text] [Related]
23. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis]. Simon P Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038 [No Abstract] [Full Text] [Related]
24. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Consensus conference. Paris, France, 27 June 1992. Nephrol Dial Transplant; 1993; 8 Suppl 1():1-54. PubMed ID: 8389014 [No Abstract] [Full Text] [Related]
25. Iron overload and bone disease in chronic dialysis patients. Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME Contrib Nephrol; 1988; 64():134-43. PubMed ID: 3180820 [No Abstract] [Full Text] [Related]
26. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH. Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006 [No Abstract] [Full Text] [Related]
28. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy. Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321 [No Abstract] [Full Text] [Related]
29. [Myopathies in chronic renal failure patients on dialysis]. Henning HV Dtsch Med Wochenschr; 1996 Jan; 121(4):115. PubMed ID: 8631240 [No Abstract] [Full Text] [Related]
30. Role of desferrioxamine in the treatment of dialysis encephalopathy. Ackrill P; Ralston AJ; Day JP Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985 [No Abstract] [Full Text] [Related]
31. Hyperparathyroidism and bone aluminum deposits may coexist. Olmer M; Berland Y; Toga M; Charhon S Contrib Nephrol; 1985; 49():38-44. PubMed ID: 3830569 [No Abstract] [Full Text] [Related]
32. Aluminum-associated bone disease: what's in a name? Quarles LD; Gitelman HJ; Drezner MK J Bone Miner Res; 1986 Oct; 1(5):389-90. PubMed ID: 3503553 [No Abstract] [Full Text] [Related]
33. Aluminum and the pathogenesis of dialysis encephalopathy. Arieff AI Am J Kidney Dis; 1985 Nov; 6(5):317-21. PubMed ID: 3904424 [No Abstract] [Full Text] [Related]
34. Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds. Netter P; Kessler M; Burnel D; Hutin MF; Delones S; Benoit J; Gaucher A J Rheumatol; 1984 Feb; 11(1):66-70. PubMed ID: 6699835 [TBL] [Abstract][Full Text] [Related]
35. Aluminum loading in children with chronic renal failure. Sedman AB; Miller NL; Warady BA; Lum GM; Alfrey AC Kidney Int; 1984 Aug; 26(2):201-4. PubMed ID: 6503137 [TBL] [Abstract][Full Text] [Related]
36. [Successful treatment of progressive dialysis encephalopathy. Case report]. Weiland P; Köhler M; Glatzel E Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157 [TBL] [Abstract][Full Text] [Related]
37. Aluminum in tissues. Van de Vyver FL; De Broe ME Clin Nephrol; 1985; 24 Suppl 1():S37-57. PubMed ID: 3915959 [TBL] [Abstract][Full Text] [Related]
38. Serum aluminium measurements in renal bone disease. Lancet; 1983 May; 1(8334):1168-9. PubMed ID: 6133187 [No Abstract] [Full Text] [Related]